skip to main menu

hans biomed

  • CEO
  • 우리회사는
    • 국내 1호 조직은행 설립
    • 아시아 최초 FDA 등록
    • 세계일류상품 인증기업
    • 국내 최대 조직공학 연구소 보유
    • 업계최초 코스닥 상장
  • 성장연혁
  • Vision 2022
  • 사업영역
    • Allograft Tissue
    • Silicone Polymer
    • Medical Device
    • Bio Technology
  • 인증현황
  • 글로벌 네트워크
  • 찾아오시는길

HomeHans BiomedBusiness Area

Business Area

Hans Biomed Corp. was established in 1993, and was the starting company of  Wound healing and  Scar prevention  project. With the creativity, focused attention and work of our young researches, core life-saving technologies have been developed. These core technologies were then translated into novel medical products. The products developed by the Daedeok Research Center are being exported to more than 25 countries across the world.
  • Allograft Tissue
  • Silicone Polymer
  • Medical Device
  • Bio Technology

Bio Technology

A. Self Skin Cell Treatment Agent

Self skin cell treatment agent uses cells cultured from your own tissues. It is a self-derived cell agent, so there are no risks of rejection of the agent by autoimmunity.

Healthy keratinocytes are attached to a silicone sheet for use on the patient. It is mainly used for patients with burns, chronic ulcers and diabetic ulcers, and is used for skin regeneration and would healing purposes.

The number of diabetic patients are increasing rapidly, due to changes in diet and decreased physical activity. Of these patients 15-20% develop diabetic foot ulcers. There are 1.6 million patients in the U.S. with ischemic and diabetic foot ulcers but there is no effective treatment that fulfil both economic and medical feasibility.

There is active research and development of artificial skin, which can replace the function of natural skin or induce skin regeneration. But there are many problems to prevent the production of perfect artificial skin. Artificial skin substitute has shown to promote rapid wound healing, and decrease scars, as well as other excellent qualitative wound healing effects. However, with the level of current technology, many products are using hydrated allograft or autograft collagen as the main structural component of the dermis. Yet, it holds problems such as triggering immune response, high costs, lack of strength and decreased engraftment. Insufficient blood supply causes significant decrease in the rate of engraftment and thus there are many problems with the use of these products as transplant material and mass production of these.

Self skin cell treatment agent uses cells cultured from your own tissues. It is a self-derived cell agent, so there are no risks of rejection of the agent by autoimmunity.

B. Pharmacological Agent Impregnated Bone Fillers

A sol-gel drug delivery system with osteoporosis treatment agent impregnated calcium phosphate microsphere and demineralized human bone tissue was combined to be used in patients with fractures due to osteoporosis.

Unlike those with healthy teeth, patients with osteoporosis or elderly with weak bones, may receive bone transplant in areas of bone deficit. Use of bone fillers that are used in healthy subjects leads to decreased effect of the treatment.

To solve these problems, a bone filler with impregnated osteoporosis treatment agent, a complex bone filler, is directly transplanted into the lesion of a fracture patient, to treat fracture and osteoporosis at the same time. This product is a complex bone filler with impregnated slow-release osteoporosis treatment agent, which releases the drug for 3 months after transplantation into the area of deficit to promote recovery of the bone deficit

A sol-gel drug delivery system with osteoporosis treatment agent impregnated calcium phosphate microsphere and demineralized human bone tissue was combined to be used in patients with fractures due to osteoporosis.